ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The U.S. Food & Drug Administration has sent warning letters to two Chinese pharmaceutical chemical producers. The agency says Shanghai Desano Chemical Pharmaceutical failed to fully investigate evidence of production deviations that were revealed during analytical testing. The company also conducted “unofficial” testing and kept the data in a folder called “Test.” At Chongqing Lummy Pharmaceutical, the agency found that company analysts had falsified data generated by gas chromatographs and HPLCs by setting back their clocks. FDA also discovered that Lummy operators did not make entries in batch manufacturing records at the time operations were performed but rather completed batch records in groups.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter